Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582582 · ClinicalTrials.gov registry record · Phase 2
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00582582 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 70 participants.
The verdict
NCT00582582, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out the toxicities of doxercalciferol given in combination with docetaxel (Taxotere®), as well as to see how well this combination works in the treatment of prostate cancer.
Interventions
- DRUG Docetaxel plus doxercalciferol
- DRUG Docetaxel plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2002-04 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582582
The ClinicalTrials.gov registry entry for NCT00582582 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel plus doxercalciferol is the first listed.
NCT00582582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582582 about?
NCT00582582 is a clinical study titled "Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer". The purpose of this research study is to find out the toxicities of doxercalciferol given in combination with docetaxel (Taxotere®), as well as to see how well this combination works in the treatment of prostate cancer.
What is the current status of trial NCT00582582?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2002-04. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00582582?
The interventions under investigation include: Docetaxel plus doxercalciferol (DRUG), Docetaxel plus placebo (DRUG).
Who is sponsoring clinical trial NCT00582582?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.